Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million

Dow Jones04-30 21:34

By Colin Kellaher

Hemab Therapeutics Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million.

Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share.

At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares.

Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 30, 2026 09:34 ET (13:34 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631653819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631653819","market":"us","top_or_hot":-1,"title":"Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hemab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million. \n</p>\n<p>\n  Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share. \n</p>\n<p>\n  At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares. \n</p>\n<p>\n  Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 09:34 ET (13:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-30 21:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hemab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million. \n</p>\n<p>\n  Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share. \n</p>\n<p>\n  At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares. \n</p>\n<p>\n  Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 09:34 ET (13:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631653819","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631653819","pubTimestamp":1777556040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hemab Therapeutics Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million.Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share.At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares.Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SPCX":"SPAC and New Issue ETF","IPOS":"Renaissance International IPO ETF","BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Hemab Therapeutics将IPO数量从1180万股增至1500万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"IPOS":1.5,"SPCX":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Hemab Therapeutics Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million. \n\n\n  Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share. \n\n\n  At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares. \n\n\n  Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 09:34 ET (13:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631653819","isCrawlerRequest":true}